Development of Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2022 Jul 20

PMID 35857429

Authors

Elisavet Lambidis

Chun-Chieh Chen

Mo Baikoghli

Surachet Imlimthan

You Cheng Khng

Mirkka Sarparanta

R Holland Cheng

Anu J Airaksinen

Affiliations

Soon will be listed here.

Abstract

Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.

Citing Articles

Virus-like nanoparticles as a theranostic platform for cancer.

Kim K, Lee A, Kim S, Heo H, Kim C Front Bioeng Biotechnol. 2023; 10:1106767.

PMID: 36714624 PMC: 9878189. DOI: 10.3389/fbioe.2022.1106767.

References

Lu Y, Gu Z . Kidney physiology: A size bandpass filter. Nat Nanotechnol. 2017; 12(11):1023-1025. DOI: 10.1038/nnano.2017.200. View

Velikyan I . 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules. 2015; 20(7):12913-43. PMC: 6332429. DOI: 10.3390/molecules200712913. View

Kilian K . Ga-DOTA and analogs: Current status and future perspectives. Rep Pract Oncol Radiother. 2017; 19(Suppl):S13-S21. PMC: 5394743. DOI: 10.1016/j.rpor.2014.04.016. View

Zheng Z, Miao J, Zhao M, Tang M, Yeo A, Yu H . Role of heat-shock protein 90 in hepatitis E virus capsid trafficking. J Gen Virol. 2010; 91(Pt 7):1728-36. DOI: 10.1099/vir.0.019323-0. View

Koudelka K, Manchester M . Chemically modified viruses: principles and applications. Curr Opin Chem Biol. 2010; 14(6):810-7. DOI: 10.1016/j.cbpa.2010.10.005. View

Yamashita T, Mori Y, Miyazaki N, Cheng R, Yoshimura M, Unno H . Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A. 2009; 106(31):12986-91. PMC: 2722322. DOI: 10.1073/pnas.0903699106. View

Takamura S, Niikura M, Li T, Takeda N, Kusagawa S, Takebe Y . DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. 2004; 11(7):628-35. DOI: 10.1038/sj.gt.3302193. View

Lee E, Kim J, Hur W, Choi J, Kim S, Park D . Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus. Sci Rep. 2019; 9(1):1616. PMC: 6367430. DOI: 10.1038/s41598-019-38533-7. View

Yang Y, Li H, Li Z, Zhang Y, Zhang S, Chen Y . Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens. Vaccine. 2015; 33(9):1143-50. DOI: 10.1016/j.vaccine.2015.01.031. View

10.

Jennings G, Bachmann M . The coming of age of virus-like particle vaccines. Biol Chem. 2008; 389(5):521-36. DOI: 10.1515/bc.2008.064. View

11.

Holla P, Ahmad I, Ahmed Z, Jameel S . Hepatitis E virus enters liver cells through a dynamin-2, clathrin and membrane cholesterol-dependent pathway. Traffic. 2015; 16(4):398-416. DOI: 10.1111/tra.12260. View

12.

Maraming P, Klaynongsruang S, Boonsiri P, Peng S, Daduang S, Leelayuwat C . The cationic cell-penetrating KT2 peptide promotes cell membrane defects and apoptosis with autophagy inhibition in human HCT 116 colon cancer cells. J Cell Physiol. 2019; 234(12):22116-22129. DOI: 10.1002/jcp.28774. View

13.

Himmelsbach K, Bender D, Hildt E . Life cycle and morphogenesis of the hepatitis E virus. Emerg Microbes Infect. 2018; 7(1):196. PMC: 6265337. DOI: 10.1038/s41426-018-0198-7. View

14.

Chen C, Xing L, Stark M, Ou T, Holla P, Xiao K . Chemically activatable viral capsid functionalized for cancer targeting. Nanomedicine (Lond). 2016; 11(4):377-90. PMC: 4910953. DOI: 10.2217/nnm.15.207. View

15.

Jariyapong P, Xing L, van Houten N, Li T, Weerachatyanukul W, Hsieh B . Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine. 2012; 31(2):417-24. PMC: 7901287. DOI: 10.1016/j.vaccine.2012.10.073. View

16.

Colino C, Lanao J, Gutierrez-Millan C . Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Front Immunol. 2020; 11:218. PMC: 7065596. DOI: 10.3389/fimmu.2020.00218. View

17.

Yang Y, Yu M, Zhang S, Ma G, Su Z . Adsorption of virus-like particles on ion exchange surface: Conformational changes at different pH detected by dual polarization interferometry. J Chromatogr A. 2015; 1408:161-8. DOI: 10.1016/j.chroma.2015.07.019. View

18.

Roemer R . Engineering aspects of hyperthermia therapy. Annu Rev Biomed Eng. 2001; 1:347-76. DOI: 10.1146/annurev.bioeng.1.1.347. View

19.

Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D . Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. Int J Mol Sci. 2017; 18(6). PMC: 5486072. DOI: 10.3390/ijms18061249. View

20.

Yin X, Feng Z . Hepatitis E Virus Entry. Viruses. 2019; 11(10). PMC: 6832200. DOI: 10.3390/v11100883. View